The MOTS-C spray delivers the mitochondrial-derived peptide intranasally — providing a convenient, non-injectable format for one of the most important metabolic signaling peptides in the longevity research space, with published data demonstrating AMPK activation, improved insulin sensitivity, and enhanced exercise capacity in both animal models and early human studies.

The MOTS-C spray delivers the mitochondrial-derived peptide intranasally — providing a convenient, non-injectable format for one of the most important metabolic signaling peptides in the longevity research space, with published data demonstrating AMPK activation, improved insulin sensitivity, and enhanced exercise capacity in both animal models and early human studies. MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is unique among peptides because it is encoded within the mitochondrial genome rather than nuclear DNA — making it one of only a handful of known mitochondrial-derived peptides (MDPs) that function as intercellular signaling molecules.

PSPeptides offers the MOTS-C Spray alongside the injectable vial. For a comprehensive overview of MOTS-C mechanism and evidence, see our complete MOTS-C research guide.

The Unique Origin of MOTS-C: A Mitochondrial-Encoded Peptide

MOTS-C is remarkable among research peptides because of its genomic origin. While virtually all peptides in the research space are encoded by nuclear DNA, MOTS-C is encoded within the mitochondrial genome — specifically within the 12S rRNA gene of mitochondrial DNA (mtDNA). This makes it one of only a handful of known mitochondrial-derived peptides (MDPs), alongside humanin and the small humanin-like peptides (SHLPs 1-6).

This mitochondrial origin is biologically significant. Mitochondria have their own circular genome (16,569 base pairs in humans) that is maternally inherited and encodes 13 proteins, 22 tRNAs, and 2 rRNAs essential for oxidative phosphorylation. The discovery that this genome also encodes small signaling peptides like MOTS-C — which function as intercellular messengers affecting tissues far beyond the cell of origin — fundamentally expanded our understanding of mitochondrial biology. Published research by Changhan David Lee at the University of Southern California first identified MOTS-C in 2015 and demonstrated its role as a mitochondrial-derived metabolic regulator.

The mitochondrial encoding matters for aging research because mtDNA has a higher mutation rate than nuclear DNA — it lacks the protective histone packaging and comprehensive repair mechanisms that protect nuclear DNA. As mtDNA mutations accumulate with age, the expression of mitochondrial-encoded proteins and peptides changes. Published data shows that MOTS-C levels decline with age in human skeletal muscle and plasma — suggesting that age-related mtDNA changes may reduce MOTS-C production, contributing to the metabolic dysfunction that characterizes aging. The MOTS-C spray provides exogenous replacement for this declining endogenous peptide.

MOTS-C Spray and Insulin Sensitivity Research

One of the most clinically relevant effects of MOTS-C is its ability to improve insulin sensitivity — the cellular responsiveness to insulin signaling that determines how efficiently tissues take up glucose from the bloodstream. Insulin resistance — reduced insulin sensitivity — is a hallmark of metabolic syndrome, type 2 diabetes, and age-related metabolic dysfunction. Published research has demonstrated that MOTS-C treatment in mouse models of diet-induced obesity and insulin resistance significantly improved glucose tolerance and insulin sensitivity without requiring weight loss or changes in food intake.

The mechanism operates through AMPK activation in skeletal muscle — the tissue responsible for the majority of insulin-stimulated glucose disposal. AMPK activation in muscle tissue increases the translocation of glucose transporters (GLUT4) to the cell surface, enhancing glucose uptake independently of insulin signaling. This means MOTS-C may improve glucose homeostasis through a pathway that supplements rather than depends on the insulin receptor — a mechanistic distinction relevant to researchers studying conditions where insulin signaling itself is impaired.

For researchers studying metabolic peptides through different receptor systems, our weight loss peptide guide covers GLP-1-based compounds like retatrutide that improve metabolic health through appetite suppression and incretin signaling. MOTS-C and GLP-1 agonists address metabolic dysfunction through completely different pathways — AMPK-mediated cellular energy regulation (MOTS-C) versus receptor-mediated appetite and insulin modulation (GLP-1) — and may be complementary in research protocols studying multi-mechanism metabolic intervention.

MOTS-C Spray and Exercise Biology

The “exercise mimetic” label for MOTS-C comes from published research showing it reproduces several of the metabolic adaptations that regular exercise produces. Exercise activates AMPK in skeletal muscle — the same kinase that MOTS-C activates pharmacologically. Exercise increases mitochondrial biogenesis through PGC-1α signaling — and MOTS-C’s AMPK activation feeds into the same PGC-1α pathway. Exercise improves insulin sensitivity through GLUT4 translocation — and MOTS-C achieves GLUT4 translocation through AMPK as well.

Published data showed that MOTS-C levels in human skeletal muscle increase during acute exercise, suggesting it functions as an endogenous exercise-responsive signal. The age-related decline in MOTS-C may partially explain why the metabolic benefits of exercise become harder to achieve in older populations — the endogenous exercise signal is diminished. Exogenous MOTS-C administration via the spray format may supplement this declining signal, potentially supporting the metabolic adaptations that exercise normally produces.

MOTS-C Spray and Body Composition Research

The body composition effects of MOTS-C are distinct from appetite-suppressing peptides in the GLP-1 class. While compounds like retatrutide and semaglutide produce weight loss primarily through reduced food intake (creating a caloric deficit that burns both fat and lean tissue), MOTS-C’s AMPK-mediated effects specifically enhance fatty acid oxidation — the metabolic pathway that breaks down stored fat for energy. Published mouse studies showed that MOTS-C treatment reduced fat accumulation on high-fat diets without changes in food intake — meaning the body composition improvement came from increased metabolic processing of fat rather than reduced caloric consumption.

This mechanism has important implications for body composition quality. Weight loss from caloric deficit (GLP-1 approach) typically includes approximately 30-40% lean tissue loss along with fat loss. Weight management through enhanced fatty acid oxidation (MOTS-C approach) may theoretically preserve more lean mass while preferentially reducing fat — though this hypothesis requires human clinical confirmation. For researchers studying body composition preservation alongside fat loss, our muscle growth and recovery guide covers peptides that support lean mass through GH and IGF-1 pathways, which are mechanistically complementary to MOTS-C’s AMPK-mediated metabolic effects.

The MOTS-C spray format enables daily administration for the extended protocols (typically 4-12 weeks) needed to observe meaningful body composition changes. The convenience of intranasal spray versus daily injection supports the protocol compliance essential for detecting metabolic and composition endpoints that develop gradually over weeks rather than days.

For researchers studying exercise biology and performance, the spray format provides a practical daily delivery route for protocols that evaluate whether sustained MOTS-C exposure produces the same long-term metabolic adaptations as regular physical activity. Our muscle growth and recovery guide covers other peptides studied for exercise-related outcomes through different mechanisms including GH secretagogues and tissue repair peptides.

Why Deliver MOTS-C as a Nasal Spray?

MOTS-C’s primary effects involve systemic metabolic regulation — AMPK activation, glucose metabolism modulation, and mitochondrial biogenesis signaling across multiple tissues including skeletal muscle, adipose tissue, and the brain. The nasal spray format provides intranasal absorption into systemic circulation while bypassing GI degradation and first-pass hepatic metabolism, potentially improving the bioavailability of this 16-amino-acid peptide compared to oral delivery.

For the brain-specific effects of MOTS-C — including its potential role in neuronal metabolic regulation and neuroprotection — the nose-to-brain delivery pathway may provide an advantage over systemic administration by delivering MOTS-C directly to CNS tissue via olfactory and trigeminal nerve transport. Published research has documented MOTS-C expression in brain tissue, and its AMPK-activating mechanism is relevant to neuronal energy homeostasis — making the potential for direct CNS delivery through the nasal route scientifically meaningful.

The practical convenience is equally important. MOTS-C research protocols typically involve daily administration over extended periods to observe metabolic and body composition effects. The spray format eliminates the daily reconstitution, syringe preparation, and injection procedure that can become compliance barriers over weeks-long protocols. For researchers studying how MOTS-C fits into the broader mitochondrial peptide landscape, our SS-31 guide covers a complementary peptide that addresses mitochondrial membrane structure (cardiolipin stabilization) rather than MOTS-C’s metabolic signaling pathway.

How Does MOTS-C Work as a Metabolic Signaling Peptide?

MOTS-C activates AMP-activated protein kinase (AMPK) — the master energy sensor and metabolic regulator in every cell. When cellular energy is low (high AMP-to-ATP ratio), AMPK activates catabolic pathways that generate ATP (fatty acid oxidation, glucose uptake, mitochondrial biogenesis) while suppressing anabolic pathways that consume ATP (lipogenesis, gluconeogenesis, protein synthesis). MOTS-C activates AMPK even in energy-replete conditions — essentially mimicking the metabolic signature of exercise at the cellular level, which is why MOTS-C has been called an “exercise mimetic” peptide.

Published research from the Lee laboratory at the University of Southern California demonstrated that MOTS-C treatment in mice improved insulin sensitivity, increased glucose uptake in skeletal muscle, reduced fat accumulation on high-fat diets, and enhanced physical performance on exercise testing — effects consistent with the metabolic profile produced by regular exercise. A small human study showed that MOTS-C levels in skeletal muscle increase during exercise and decline with age, suggesting that age-related MOTS-C decline may contribute to the metabolic dysfunction associated with aging.

The AMPK activation mechanism connects MOTS-C to the broader NAD+-sirtuin axis that is central to longevity research. AMPK and sirtuins form a mutually reinforcing metabolic signaling network — AMPK activation increases NAD+ levels (by stimulating the NAD+ salvage pathway), which in turn activates NAD+-dependent sirtuins (SIRT1, SIRT3), which further enhance metabolic efficiency. This positive feedback loop may explain why combining MOTS-C spray with NAD+ spray is theoretically synergistic — MOTS-C activates the signaling pathway (AMPK) while NAD+ provides the substrate that sirtuins require.

MOTS-C Spray for Metabolic and Longevity Research

The research applications for MOTS-C spray span metabolic health, exercise physiology, and aging biology.

Metabolic health: MOTS-C’s AMPK-mediated effects on glucose metabolism, insulin sensitivity, and fatty acid oxidation make it relevant to metabolic syndrome and type 2 diabetes research. The spray format provides a convenient daily delivery route for the extended protocols that metabolic research requires. For researchers studying metabolic peptides through different mechanisms, our weight loss peptide guide covers GLP-1-based compounds like retatrutide that address metabolism through appetite suppression rather than AMPK activation.

Exercise mimetics: MOTS-C’s ability to produce exercise-like metabolic effects — improved insulin sensitivity, enhanced fatty acid oxidation, increased mitochondrial biogenesis — positions it in the growing “exercise mimetic” research category alongside compounds that activate exercise-related signaling pathways pharmacologically. The spray format is practical for daily administration protocols that study whether sustained MOTS-C exposure produces the same long-term metabolic adaptations as regular physical exercise.

Longevity: Published data showing age-related MOTS-C decline across tissues, combined with its AMPK-activating mechanism that intersects with the NAD+-sirtuin longevity axis, makes MOTS-C relevant to biological aging research. For comprehensive longevity protocols, the MOTS-C spray can be combined with Epitalon spray (telomere maintenance), NAD+ spray (sirtuin activation), and GHK-Cu spray (tissue regeneration). Our longevity peptide guide covers the broader landscape.

MOTS-C Spray and Mitochondrial Biogenesis

Beyond AMPK activation and its immediate metabolic effects, MOTS-C stimulates mitochondrial biogenesis — the process of creating new mitochondria within cells. Published research has shown that AMPK activation by MOTS-C increases the expression of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis that coordinates the nuclear and mitochondrial gene expression programs required to build new mitochondria.

This mitochondrial biogenesis effect is particularly relevant to aging research because mitochondrial number and function decline progressively with age. Aged skeletal muscle contains fewer mitochondria with reduced respiratory capacity, contributing to the fatigue, reduced exercise tolerance, and metabolic dysfunction that characterize biological aging. By stimulating the production of new, functional mitochondria, MOTS-C may partially counteract the age-related decline in cellular energy production capacity.

The MOTS-C spray delivers this mitochondrial biogenesis signal intranasally, with potential nose-to-brain transport that could affect neuronal mitochondria — particularly relevant because the brain’s enormous energy demands make it exquisitely sensitive to mitochondrial dysfunction. For researchers studying mitochondrial biology through complementary mechanisms, SS-31 (elamipretide) stabilizes existing mitochondrial membrane structure (cardiolipin protection), while MOTS-C stimulates the creation of new mitochondria (biogenesis). NAD+ provides the substrate that mitochondrial enzymes and sirtuins require. Together, these three compounds — all available as PSPeptides sprays — address mitochondrial aging from the structural (SS-31), metabolic signaling (MOTS-C), and substrate availability (NAD+) dimensions simultaneously.

The MOTS-C spray’s convenience supports the extended daily protocols needed to observe mitochondrial biogenesis effects. Unlike acute metabolic changes (like improved insulin sensitivity, which can be measured within days), mitochondrial biogenesis requires sustained signaling over weeks to produce measurable increases in mitochondrial density and respiratory capacity. The spray format removes the compliance barriers that can compromise multi-week protocols requiring daily peptide administration.

MOTS-C Spray Dosing and Protocols

The PSPeptides MOTS-C Spray is pre-formulated and ready to use. Administer intranasally with head tilted slightly back, alternating nostrils. Published research protocols vary in dosing, but the pre-calibrated spray format ensures consistent delivery per actuation — an advantage over injectable protocols where reconstitution concentration and syringe drawing precision can introduce dosing variability.

Timing of administration may be relevant depending on the research question. For metabolic research focused on glucose disposal and insulin sensitivity, morning administration may capitalize on the natural circadian peak in metabolic activity and postprandial glucose challenge. For exercise mimetic research, administration before physical activity protocols may enhance the AMPK-mediated metabolic response to exercise — amplifying the endogenous exercise signal with exogenous MOTS-C support. For general longevity protocols, consistent daily timing is more important than the specific time chosen.

The spray format is particularly advantageous for combination longevity protocols that include multiple daily peptides. Researchers administering MOTS-C spray alongside NAD+ spray and Epitalon spray can complete a three-compound longevity protocol in under two minutes of total administration time — compared to the 15-20 minutes required to reconstitute, draw, and inject three separate peptide vials. For researchers who prefer the injectable format, our reconstitution guide and dosage calculator cover preparation. Storage at 2-8°C per our storage guide.

Further Reading

For additional peer-reviewed research, see: PubMed research on MOTS-C and AMPK activation.

Understanding mots-c spray is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is MOTS-C and why is it called an exercise mimetic?

MOTS-C is a mitochondrial-derived peptide that activates AMPK — the master energy sensor that coordinates the metabolic response to exercise. Published research showed MOTS-C produces exercise-like metabolic effects including improved insulin sensitivity, enhanced fatty acid oxidation, and increased mitochondrial biogenesis, earning it the “exercise mimetic” designation.

Why use a MOTS-C spray instead of injectable?

The spray provides intranasal absorption bypassing GI degradation and first-pass metabolism, with potential nose-to-brain delivery for CNS metabolic effects. It eliminates daily reconstitution and injection for the extended protocols metabolic research requires.

Can the MOTS-C spray be combined with NAD+ spray?

Yes, and this combination is mechanistically synergistic. MOTS-C activates AMPK, which increases NAD+ levels through the salvage pathway. NAD+ spray provides additional substrate for NAD+-dependent sirtuins. Together they reinforce the AMPK-NAD+-sirtuin metabolic axis from two entry points.

How does MOTS-C spray compare to SS-31?

They address different aspects of mitochondrial biology. MOTS-C activates AMPK metabolic signaling — the cell’s energy sensing and regulation system. SS-31 stabilizes cardiolipin in the inner mitochondrial membrane — protecting electron transport chain structure. They are complementary rather than redundant.

All PSPeptides products are sold exclusively for research and laboratory use.